Diagnostyka’s journey to IPO: an investor case study

Diagnostyka’s journey to IPO: an investor case study

Maple Room

Information

Diagnostyka recently debuted on the Warsaw Stock Exchange in a €400m IPO, which allowed MidEuropa to fully realise its investment. During MidEuropa’s partnership with the company, Diagnostyka expanded through over 120 acquisitions, driving consistent revenue growth of 24 per cent per annum. We ask Matthew Strassberg about his experience supporting the company through its gradual transformation from a regional, founder-led business into a $1bn market cap national champion. What learnings does he take away from the journey? What can we conclude from the significant interest from international and domestic investors in the IPO for the sector and the region?

Rothschild & CoRothschild Meeting Suite - C29+C31Rothschild & Co is one of the world’s largest independent financial advisory groups, with 4,200 people in over 40 countries worldwide. Our Global Advisory business has an impartial and insightful perspective on M&A, strategy and financing advisory to help our clients formulate and achieve their strategic goals.We are one of the most active advisers to the Healthcare sector globally and the most active in Europe.  This provides our dedicated healthcare team of over 35 bankers in London with exceptional insight into the sector, and the experience to advise on the most complex transactions.

Registered attendees

Ana Neves
Ana Neves
Global Head of Strategic Marketing - ZEISS OphthalmologyZEISS Meditec
Ana-Maria Pascu
Ana-Maria Pascu
M&A DirectorRegina Maria
Anastacia Ruszczyk
Anastacia Ruszczyk
Associate DirectorUBS

Log in

See all the content and easy-to-use features by logging in or registering!